Posted by Michael Wonder on 29 Apr 2024
Soleno Therapeutics receives breakthrough therapy designation from US FDA for diazoxide choline extended release tablets in Prader-Willi syndrome
29 April 2024 - Designation is based on data from the Phase 3 program for diazoxide choline.
Soleno Therapeutics today announced that the US FDA has granted breakthrough therapy designation to diazoxide choline for the treatment of adults and children ages 4 years and older with genetically confirmed Prader-Willi syndrome who have hyperphagia.
